Xenon to Report Q2 2025 Financial Results on August 11, 2025
Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, will report its Q2 2025 financial results on Monday, August 11, 2025, after U.S. market close. The company will host a conference call at 4:30 PM ET to discuss results and provide business updates.
Xenon is advancing an ion channel product portfolio focused on epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (NASDAQ: XENE), un'azienda biofarmaceutica specializzata in neuroscienze, comunicherà i suoi risultati finanziari del secondo trimestre 2025 il lunedì 11 agosto 2025, dopo la chiusura del mercato statunitense. L'azienda terrà una conference call alle 16:30 ET per discutere i risultati e fornire aggiornamenti sul business.
Xenon sta sviluppando un portafoglio di prodotti a base di canali ionici focalizzati sull'epilessia e la depressione. Il loro candidato principale, azetukalner, è un apritore del canale potassio Kv7 in fase clinica avanzata per diverse indicazioni.
Xenon Pharmaceuticals (NASDAQ: XENE), una empresa biofarmacéutica centrada en neurociencia, reportará sus resultados financieros del segundo trimestre de 2025 el lunes 11 de agosto de 2025, después del cierre del mercado estadounidense. La compañía realizará una conferencia telefónica a las 4:30 PM ET para discutir los resultados y ofrecer actualizaciones sobre el negocio.
Xenon está avanzando en un portafolio de productos de canales iónicos enfocado en epilepsia y depresión. Su candidato principal, azetukalner, es un activador del canal de potasio Kv7 en desarrollo clínico avanzado para múltiples indicaciones.
Xenon Pharmaceuticals (NASDAQ: XENE)는 신경과학에 중점을 둔 바이오제약 회사로서, 2025년 2분기 재무 실적을 2025년 8월 11일 월요일 미국 시장 마감 후에 발표할 예정입니다. 회사는 동부시간 오후 4시 30분에 실적과 사업 현황을 논의하기 위한 컨퍼런스 콜을 개최합니다.
Xenon은 간질과 우울증에 중점을 둔 이온 채널 제품 포트폴리오를 발전시키고 있습니다. 주력 후보 물질인 azetukalner는 다중 적응증을 위한 후기 임상 개발 단계에 있는 Kv7 칼륨 채널 개방제입니다.
Xenon Pharmaceuticals (NASDAQ : XENE), une entreprise biopharmaceutique spécialisée en neurosciences, publiera ses résultats financiers du deuxième trimestre 2025 le lundi 11 août 2025, après la fermeture du marché américain. La société organisera une conférence téléphonique à 16h30 ET pour discuter des résultats et fournir des mises à jour sur ses activités.
Xenon fait progresser un portefeuille de produits ciblant les canaux ioniques, axé sur l’épilepsie et la dépression. Leur principal candidat, azetukalner, est un activateur du canal potassique Kv7 en phase clinique avancée pour plusieurs indications.
Xenon Pharmaceuticals (NASDAQ: XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, wird seine Finanzergebnisse für das 2. Quartal 2025 am Montag, den 11. August 2025, nach Börsenschluss in den USA, bekannt geben. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Geschäftsaktualisierungen zu geben.
Xenon entwickelt ein Portfolio von Ionenkanalprodukten mit Fokus auf Epilepsie und Depression. Ihr führender Kandidat, azetukalner, ist ein Kv7-Potassiumkanalöffner in der späten klinischen Entwicklungsphase für mehrere Indikationen.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025.
Conference Call/Webcast Information:
| Date: | Monday, August 11, 2025 | |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) | |
| Webcast: | Pre-register here | |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers | |
| Conference ID: | 4102397 | |
A live webcast of the company presentation will be available on the Investors section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When will Xenon (XENE) report Q2 2025 earnings?
How can investors access Xenon's Q2 2025 earnings call?
What is Xenon's lead drug candidate?
What therapeutic areas does Xenon focus on?
